Sign In
Buy PRTA
$8.12
-0.290 (-3.45%)
At Close: Jul 31, 2026
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
11:50am, Monday, 11'th Nov 2024
Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.
Prothena to Report Third Quarter 2024 Financial Results on November 12
04:05pm, Tuesday, 05'th Nov 2024
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will report its third quarter and first nine months of 2024 financial results on Tuesday, November 12, 2024.
Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Tuesday, 29'th Oct 2024
Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength?
05:50am, Tuesday, 29'th Oct 2024
Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro
Prothena Announces Leadership Team Updates
04:05pm, Friday, 27'th Sep 2024
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that Chad Swanson, Ph.D., has been appointed Chief Development Officer.
What Makes Prothena (PRTA) a New Buy Stock
01:01pm, Monday, 19'th Aug 2024
Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues
10:21am, Friday, 09'th Aug 2024
Prothena (PRTA) records impressive second-quarter earnings as the top line benefits from a $80-million payment from collaboration partner BMY.
Prothena (PRTA) Q2 Earnings and Revenues Beat Estimates
07:41pm, Thursday, 08'th Aug 2024
Prothena (PRTA) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of a loss of $1.01 per share. This compares to loss of $1.03 per share a year ago.
Prothena to Report Second Quarter 2024 Financial Results on August 8
04:05pm, Thursday, 01'st Aug 2024
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will report its second quarter and first six months of 2024 financial results on Thursday, August 8, 2024.
Prothena (PRTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
11:07am, Thursday, 25'th Jul 2024
Prothena (PRTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?
09:50am, Monday, 24'th Jun 2024
Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
12:20pm, Tuesday, 11'th Jun 2024
Eli Lilly stock reversed premarket gains at the open Tuesday after an FDA panel endorsed its Alzheimer's treatment, donanemab.
Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?
12:36pm, Friday, 07'th Jun 2024
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?
Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
11:31am, Wednesday, 29'th May 2024
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that Bristol Myers Squibb obtained the exclusive global license for PRX019 and will pay Prothena $80 million.
